Equity Overview
Price & Market Data
Price: $0.929
Daily Change: +$0.059 / 6.35%
Range: $0.828 - $0.929
Market Cap: $5,650,419
Volume: 61,755
Performance Metrics
1 Week: 15.72%
1 Month: -36.11%
3 Months: -57.41%
6 Months: -57.99%
1 Year: -88.64%
YTD: -59.47%
Company Details
Employees: 27
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.